hepatocellular carcinoma – Rogalevich http://rogalevich.org/ Sat, 26 Mar 2022 12:35:19 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://rogalevich.org/wp-content/uploads/2021/10/icon-120x120.png hepatocellular carcinoma – Rogalevich http://rogalevich.org/ 32 32 Exelixis throws in the towel on early-stage liver cancer after final reading shows OS flop – Endpoints News https://rogalevich.org/exelixis-throws-in-the-towel-on-early-stage-liver-cancer-after-final-reading-shows-os-flop-endpoints-news/ Tue, 15 Mar 2022 10:36:01 +0000 https://rogalevich.org/exelixis-throws-in-the-towel-on-early-stage-liver-cancer-after-final-reading-shows-os-flop-endpoints-news/ The door to a label expansion for Exelixis’ Cabometyx is now completely closed. Exelixis held out a glimmer of hope – however slim – in the summer of last year, when it published mixed results from an interim reading of a phase III trial testing a combination of Cabometyx and Tecentriq from Roche versus Bayer’s […]]]>

The door to a label expansion for Exelixis’ Cabometyx is now completely closed.

Exelixis held out a glimmer of hope – however slim – in the summer of last year, when it published mixed results from an interim reading of a phase III trial testing a combination of Cabometyx and Tecentriq from Roche versus Bayer’s Nexavar in previously untreated liver cancer. But the final analysis turned out to be equally disappointing, as the combo was tied to “neither improvement nor detriment to the operating system”.

No numbers were provided – they are on file for a later medical meeting – but biotechnology has made it clear that this is now the end of the road.

Based on this OS result and the rapidly changing treatment landscape for previously untreated advanced HCC, Exelixis does not intend to submit an additional New Drug Application to the Food and Drug Administration ( FDA) of the United States.

Cabometyx, a tyrosine kinase inhibitor that hits a range of targets, has seen more than its share of ups and downs throughout the development journey. Two years before its first approval for second-line kidney cancer in 2016, the drug failed a key trial in prostate cancer.

Yet Exelixis continued to push for new indications, including through combined checkpoint approaches – leading to additional approvals in previously treated hepatocellular carcinoma (for liver cancer patients who have previously treated with Nexavar) and first-line renal cell carcinoma (in combination with Bristol Myers Squibb’s PD-1 Opdivo).

Vicki Goodman

The latest study, dubbed COSMIC-312, recruited 837 patients and focused on the first-line HCC setting.

Meanwhile, Cabometyx plus Tecentriq reduced the risk of disease progression or death by 37% compared to Nexavar. But it didn’t reach statistical significance on the OS, hinting at the end results – Exelixis admitted at the time that the probability of reaching the end point in the final scan was low.

“(W)e remain steadfast on our journey to further therapies for this and other difficult-to-treat cancers,” said Vicki Goodman, Chief Medical Officer.

]]>
Hepatocellular carcinoma (HCC) related to non-alcoholic fatty liver disease differs clinically from HCC due to other causes https://rogalevich.org/hepatocellular-carcinoma-hcc-related-to-non-alcoholic-fatty-liver-disease-differs-clinically-from-hcc-due-to-other-causes/ Tue, 15 Mar 2022 07:26:38 +0000 https://rogalevich.org/hepatocellular-carcinoma-hcc-related-to-non-alcoholic-fatty-liver-disease-differs-clinically-from-hcc-due-to-other-causes/ 1. Patients with NAFLD-related HCC have longer disease-free survival than those with HCC from other causes. 2. Tumors from patients with HCC related to NAFLD were often larger in diameter than patients with HCC from other causes. Level of evidence assessment: 1 (Excellent) Summary of the study: This systematic review and meta-analysis aimed to compare […]]]>

1. Patients with NAFLD-related HCC have longer disease-free survival than those with HCC from other causes.

2. Tumors from patients with HCC related to NAFLD were often larger in diameter than patients with HCC from other causes.

Level of evidence assessment: 1 (Excellent)

Summary of the study: This systematic review and meta-analysis aimed to compare the clinical presentation and outcome of hepatocellular carcinoma (HCC) due to non-alcoholic fatty liver disease (NAFLD) with HCC from other causes. Outcome measures of interest included: proportion of HCC secondary to NAFLD as well as a comparison of patient and tumor characteristics, overall survival (OS) and disease-free survival outcomes, and other measures between NAFLD-related HCC and HCC due to other causes. The proportion of HCC secondary to NAFLD was 15.1% and an increasing trend over time was noted. Patients who had HCC due to NAFLD were older with higher BMI and had a higher likelihood of comorbidities, including diabetes, hypertension, hyperlipidemia, or cardiovascular disease, compared to patients with HCC due to other causes. Patients with NAFLD-related HCC also had a higher likelihood of being non-cirrhotic. The tumors of patients with HCC due to NAFLD were larger in diameter and these patients had a higher likelihood of uninodular lesions. OS results did not differ between patients with HCC due to NAFLD and those with HCC from other causes, but disease-free survival was longer in patients with HCC due to NAFLD. Limitations of this study include those intrinsic to the meta-analyses, the exclusion of pediatric populations, and a smaller number of studies from the Southeast Asian and South American regions. Overall, the proportion of HCCs linked to NAFLD is increasing over time and an increase in surveillance strategies would be valuable for high-risk patients with NAFLD.

Click to read the study in The Lancet Oncology

Relevant reading: Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease

In depth [systematic review and meta-analysis]: This systematic review and meta-analysis included 94,636 patients in 61 studies from many countries completed between January 1980 and May 2021. The proportion of HCC secondary to NAFLD was 15.1% (95% confidence interval (CI) , 11.9%-18.9%). Patients with HCC due to NAFLD had higher BMI (mean difference 2.99 kg/m^2, 95% CI 2.20 – 3.78 kg/m^2) and were older ( mean difference 5.62 years, 95% CI 4.63 – 6.61 years). Patients with NAFLD-related HCC had a higher likelihood of comorbidities, including diabetes (odds ratio (OR) 4.31, 95% CI 3.19, 5.80), hypertension (OR 2.84, 95% CI, 2.09 – 3.86), hyperlipidemia (OR 3.43, 95% CI, 2.39 – 4.95) or cardiovascular disease (OR 2.23, 95% CI, 1.43, 3.48) compared to patients with HCC due to other causes. Patients with NAFLD-related HCC also had a higher probability of being non-cirrhotic: 38.5% (95% CI, 27.9% – 50.2%) versus 14.6% (CI at 95%, 8.7% – 23.4%). NAFLD HCC patients often had larger diameter tumors (mean difference 0.67 cm, 95% CI 0.35 to 0.98 cm) and more often uninodular lesions (OR 1.36; CI at 95%, 1.19 to 1.56). Comparison of OS results revealed that there was no difference between the groups (risk ratio (HR) 1.05; 95% CI, 0.92, 1.20). However, patients with NAFLD-related HCC had increased disease-free survival (HR 0.79; 95%, 0.63-0.99).

Picture: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No work may be reproduced without the express written consent of 2 Minute Medicine, Inc. Learn about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

]]>
Positive results in the early detection of liver cancer https://rogalevich.org/positive-results-in-the-early-detection-of-liver-cancer/ Tue, 08 Mar 2022 02:21:21 +0000 https://rogalevich.org/positive-results-in-the-early-detection-of-liver-cancer/ Helio Health, an AI-driven healthcare company focused on commercializing tests for early detection of cancer from a simple blood draw, today announced that Hepatology Communications has released positive results from the ENCORE study validating the strong clinical performance of HelioLiver in detecting the presence of early hepatocellular carcinoma (HCC), the most common form of liver […]]]>

Helio Health, an AI-driven healthcare company focused on commercializing tests for early detection of cancer from a simple blood draw, today announced that Hepatology Communications has released positive results from the ENCORE study validating the strong clinical performance of HelioLiver in detecting the presence of early hepatocellular carcinoma (HCC), the most common form of liver cancer and the seventh most common cancer in the world, but the second in terms of cancer-related mortality, often due to late diagnosis.1 In this prospective, multicenter, blinded phase 2 study, HelioLiver demonstrated high specificity %) and high sensitivity (76%) in detecting the Early-stage HCC (stage I and II), significantly outperforming other clinically available detection tools such as AFP (57%), GALAD (65%) and ultrasound (47%). 2,3 Considering HCC as a whole, HelioLiver performed at 85% sensitivity with the same specificity of 91%.2

Diagnostic tests for HCC Early Stage Susceptibility (I + II) Overall Sensitivity
HelioLiver2 76% 85%
PFA (≥ 20 ng/mL)2 57% 62%
GALAD score (≥ -0.63)2 65% 75%
Ultrasound3 47% 84%
Note: Table shows HelioLiver sensitivities at 91% specificity2
2 Lin N, et al. 2021.
3 Tzartzeva K, et al. 2018.

Helio has developed its next-generation sequencing platform, ECLIPSETM, to identify 77 methylation targets across 28 genes. These DNA markers work in combination with serum HCC proteins AFP, AFP-L3% and DCP to enhance the multi-analyte algorithm.

• The area under receiver operating characteristic (AUROC) for HelioLiver was 0.944, demonstrating significantly better predictive ability than the other tests.

• At a fixed specificity of 87.5%, HelioLiver achieved 87% sensitivity for early stage HCC and 90% overall sensitivity.

• 10 of the 28 genes used in the HelioLiver assay were found to be directly involved in molecular pathways known to be involved in the pathogenesis of HCC while only one of the 497 genes studied but not selected met the same criteria, suggesting that the markers in HelioLiver are more biologically relevant than tests that use these other genes.

Hepatology Communications is the official open access, peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD), dedicated to the rapid dissemination of high-quality research in hepatology. AASLD is the most respected medical guidelines organization for liver disease in the United States.

HelioLiver is being further evaluated in Helio’s prospective pivotal biomarker study, CLiMB (NCT03694600), where test performance will be directly compared to ultrasound using multiphasic MRI as the standard of care for the diagnosis of HCC.

No keywords for this post.

]]>
Supporting the 3rd leading cause of cancer-related death https://rogalevich.org/supporting-the-3rd-leading-cause-of-cancer-related-death/ Mon, 07 Mar 2022 15:18:52 +0000 https://rogalevich.org/supporting-the-3rd-leading-cause-of-cancer-related-death/ Liver cancer is the third leading cause of cancer-related death worldwide, and the incidence of primary liver cancer in the United States has tripled over the past four decades. While chronic viral hepatitis is the primary route to liver cancer in the United States, non-infectious causes such as morbid obesity, type 2 diabetes, non-alcoholic fatty […]]]>

Liver cancer is the third leading cause of cancer-related death worldwide, and the incidence of primary liver cancer in the United States has tripled over the past four decades. While chronic viral hepatitis is the primary route to liver cancer in the United States, non-infectious causes such as morbid obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and non-infectious steatohepatitis associated alcoholism (NASH) increased rapidly. We will describe each of these pathways, starting with viral hepatitis (HCV and HBV) and alcoholic cirrhosis.


There is a morbid saying that cancer eventually affects us all, unless something else affects us first.

While some cancers currently have no accessible prevention, some can be effectively prevented. Hepatocellular carcinoma (HCC) is one of those that can be prevented, but once HCC is established and symptomatic, survival rates drop sharply. While liver cancer is the 8and location of cancer site by prevalence (Figure 1), this is the 3rd leading cause of death (Figure 2). HCC has a high mortality profile with a median survival after diagnosis of 6-20 months, and in the United States it has a 5-year survival rate of only 10% (Golabi, et al., 2017)

Figure 1. Top 10 cancer sites by case (Sung et al, 2021)

Top 10 cancer sites by death

Figure 2. Top 10 cancer sites by death (Sung et al, 2021)

The COVID-19 pandemic has rightly occupied the minds and efforts of nearly everyone in healthcare for the past two years, but HCC has not gone away and continues to cause daily damage. . HCC was on 4and leading cause of cancer-related death in 2019 (Yang et al., 2019), and has been steadily increasing – it has tripled in the United States (Rawla, Sunkara, Muralidharan & Raj, 2018).

Although your daily chance of encountering a patient with HCC is still small, it increases year by year and there is a serious risk of missing the window of opportunity to prevent full-blown HCC.

This blog will describe how to be alert to the causes and cases of HCC, and we will provide you with tools and resources to help you identify HCC, ways to connect your patient with appropriate specialists, and help you find appropriate studies and trials for your patient.

There are four main HCC risk factors:

  1. Hepatitis B (HBV)
  2. Hepatitis C (HCV)
  3. Excessive consumption of alcohol
  4. Non-alcoholic fatty liver disease (NAFLD) resulting in non-alcoholic steatohepatitis (NASH)

How likely are you to encounter hepatocellular carcinoma in patients?

In the near future, it is unlikely that any specific patient you see will already have HCC. That’s great, but it’s also a problem because you’re less likely to recognize it immediately. For HCC, delay is the killer.

However, you are very likely to see a patient who, regardless of their primary complaint, is already on one or more of the four main HCC pathways. The picture is also skewed when race is taken into account – while the overall rate of HBV infection has declined significantly since 1991, it remains a concern for the African American population. In 2017, non-Hispanic African Americans were 1.5 times more likely to die from viral hepatitis than whites, and almost twice as likely to die from HCV. (HHS-OMH”Hepatitis and African Americans”)

Anything you can do to increase HBV vaccination rates and prevent HCV infection will help steer your patients away from the viral pathway. It is therefore important to use screening tests for HBV and HCV and to strongly encourage HBV vaccination even if patients are not in high-risk categories. Likewise, addressing alcohol use and encouraging your patients to follow guidelines will help steer them away from alcohol’s path to HCC.

the NAFLD/NASH pathway talks about lifestyle changes that are inherently healthier and worth discussing. Discussing healthy eating, limiting portion sizes, and maintaining a healthy weight with your patients can help steer them away from this path.

Patient history that should raise your index of suspicion includes past unprotected sex, use of needles, binge drinking or binge drinking, or increasing obesity. However, it is important to keep in mind that many patients who had no obvious risk factors in their history nevertheless went on to have HCC. Although atypical, HCC can be the result of maternal HBV infection or HCV transmitted to children. For an example, see “Better off bald: a life in 147 days

How to discuss staging with patients

Discussing staging with patients can be difficult, and the literature is often either aimed at clinicians or contains misleading information. Blue Faery provides clinically accurate yet understandable materials to help you describe the staging and help the patient understand where they are on the spectrum.

These materials include:

  • The HCC patient education brochures is written in plain language and intended to be read by the patient.
  • The Blue Faery and Exelixis staging discussion pad contains anatomical graphics and easy-to-understand text. Each double-sided sheet allows the doctor to add notes that his patient can use after the appointment.
  • the Liver Cancer Patient Resource Guide is a 20-page booklet containing relevant explanations and resources for HCC patients and their caregivers.

Blue Faery will send these documents free of charge to any doctor who requests them.

How to Find Hepatocellular Carcinoma Specialists, Treatment Options and Clinical Trials

Treatment of HCC is best approached with a multidisciplinary team coordinated by a primary care physician. The most effective approach will likely require the expertise of multiple healthcare professionals, including the primary care physician, and may include an oncologist with experience in HCC, gastroenterologist, hepatologist, radiologist interventionist, a radiation oncologist, a surgical oncologist and a transplant surgeon.

Where to find clinical trials specific to hepatocellular carcinoma

To find all clinical trials, the best option is clinicaltrials.gov, but this website can be confusing and difficult to navigate. To help physicians guide their patients to relevant trials, Blue Faery has a custom HCC clinical trial browser.

Where can patients find community support?

Patient communities are very helpful in providing patients with practical guidance for their care journey and are often a source of emotional support from people who understand the experience.

the Blue Fairy Liver Cancer Community is a free, HIPAA-compliant online community where patients and caregivers are invited to join and seek or exchange relevant information about HCC care. Members ask questions, discuss concerns and find common ground along their cancer journey. Forum moderators include Community Ambassadors who were former caregivers of HCC patients.

For individual patient support, Blue Faery has partnered with Imerman Angels, a non-profit organization that provides peer-to-peer support services to the liver cancer community. Blue Faery and Imerman Angels believe that no one should face cancer alone.

Conclusion

With proper screening, testing and inoculation, the viral pathway to HCC can often be interrupted. Blue Faery provides free, patient-readable and clinically accurate materials to help physicians discuss their patients’ staging, options and resources.

]]>
New trial aims to test non-invasive treatment for early-stage liver cancer https://rogalevich.org/new-trial-aims-to-test-non-invasive-treatment-for-early-stage-liver-cancer/ Sat, 26 Feb 2022 04:28:00 +0000 https://rogalevich.org/new-trial-aims-to-test-non-invasive-treatment-for-early-stage-liver-cancer/ Researchers are set to test a non-invasive treatment for inoperable early-stage liver cancer, thanks to an injection of more than $2 million in federal government funding. Led by Professor Alan Wigg of Flinders University College of Medicine and Public Health, the trial aims to test stereotactic ablative body radiation therapy (SABR), a non-invasive technique that […]]]>

Researchers are set to test a non-invasive treatment for inoperable early-stage liver cancer, thanks to an injection of more than $2 million in federal government funding.

Led by Professor Alan Wigg of Flinders University College of Medicine and Public Health, the trial aims to test stereotactic ablative body radiation therapy (SABR), a non-invasive technique that delivers high doses of radiation very precisely. .

Currently, the standard of care for hepatocellular carcinoma (HCC), the most common type of liver cancer, is percutaneous ablation therapy, a thermal ablation treatment (using extreme temperatures to remove the cancer) that is given directly into the tumor using a needle. .

“Studies have shown that the current standard of care is not always effective, with cancer likely to come back in over 30% of cases, and a number of people not having access to treatment in the first place, due to the size and position of the tumour,” explains Professor Wigg.

“Stereotactic ablative body radiation therapy, on the other hand, is a relatively new radiation therapy technique that has already been used successfully to treat a number of other cancers, but it is not yet widely used to treat liver cancers. .

“It is delivered non-invasively by targeting the tumor with a number of beams of radiation from different angles, allowing delivery of a high dose and precise treatment over three to five sessions and reducing tissue damage. healthy surroundings.”

The project, a collaboration between leading haematologists, radiation oncologists and radiologists at 16 leading Australian liver centres, will carry out a randomized controlled trial to compare non-invasive treatment to the current invasive standard of care, with the possibility that the results modify the treatment. global protocols.

Currently, SBRT is considered experimental and is only used after first-line treatments have failed. However, preliminary research has shown that the treatment has the potential to control tumors with very few adverse effects and can reach those that would not be treatable by percutaneous ablation, due to the size or difficult location of a tumor. tumor.


Professor Alan Wigg, Faculty of Medicine and Public Health, Flinders University

Researchers say that with the rise in liver cancer rates in Australia, it is essential that the best treatment is proven and applied.

“Rates of hepatocellular carcinoma have risen 378% over the past 30 years, the second highest increase of any cancer type, while its death rate has seen the highest increase of any cancer,” says the Professor Wigg.

“HCC is the only low-survival cancer whose incidence is increasing rapidly. It is therefore essential that we find ways to improve patient outcomes.

“SABR may improve tumor control while being able to be administered on an outpatient basis over fewer treatment sessions, which means it is also likely to be cost effective and capable of rapid adoption into clinical practice. “

The 5-year trial will begin this year with trial sites planned in all major states in Australia.

The project, A randomized controlled trial of Sstandard OF VSare against RbyeAblahJions in Eearly SHCC study (SOCRATES HCC study), was funded by the Rare Cancers, Rare Diseases and Unmet Needs Program of the Medical Research Future Fund.

]]>
a non-invasive treatment trial will soon begin https://rogalevich.org/a-non-invasive-treatment-trial-will-soon-begin/ Fri, 25 Feb 2022 06:17:00 +0000 https://rogalevich.org/a-non-invasive-treatment-trial-will-soon-begin/ A new non-invasive treatment for inoperable early-stage liver cancer is set to be trialled across Australia this year. The trial conducted by Professor Alan Wigg of flinders university The College of Medicine and Public Health aims to test stereotactic ablative body radiation therapy (SABR), a noninvasive technique that allows precise delivery of high doses of […]]]>
Liver cancer: a non-invasive treatment trial will soon begin

A new non-invasive treatment for inoperable early-stage liver cancer is set to be trialled across Australia this year.

The trial conducted by Professor Alan Wigg of flinders university The College of Medicine and Public Health aims to test stereotactic ablative body radiation therapy (SABR), a noninvasive technique that allows precise delivery of high doses of radiation.

Currently, the standard of care for hepatocellular carcinoma (HCC), the most common type of liver cancer, is treatment with percutaneous ablation, a thermal ablation treatment delivered directly into the tumor using a needle. .

“Studies have shown that the current standard of care is not always effective, with cancer likely to come back in over 30% of cases, and a number of people not having access to treatment in the first place, due to the size and position of the tumour,” Professor Wigg said.

Stereotactic ablative body radiation therapy is a relatively new radiation therapy technique that has already been used successfully to treat a number of other cancers, but it is not yet widely used to treat liver cancers, he said. declared.

“It is delivered non-invasively by targeting the tumor with a number of beams of radiation from different angles, allowing delivery of a high dose and precise treatment over three to five sessions and reducing tissue damage. healthy surroundings.”

The project, a collaboration between leading hepatologists, radiation oncologists and radiologists at 16 leading Australian liver centres, will carry out a randomized controlled trial to compare non-invasive treatment to the current invasive standard of care, with the possibility that the results modify the treatment. global protocols.

“Currently, SBRT is considered experimental and only used after first-line treatments have failed,” Professor Wigg said.

“However, preliminary research has shown that the treatment has the potential to control tumors with very few adverse events and can reach those that would not be treatable with percutaneous ablation, due to the size or difficult location of the tumor. a tumor.”

Researchers say that with the rise in liver cancer rates in Australia, it is essential that the best treatment is proven and applied.

“Hepatocellular carcinoma rates have increased 378% over the past 30 years, the second highest increase of any cancer type, while its death rate has seen the largest increase of any cancer,” said Professor Wigg.

“HCC is the only low-survival cancer whose incidence is increasing rapidly. It is therefore essential that we find ways to improve patient outcomes.

“SABR may improve tumor control while being able to be administered on an outpatient basis over fewer treatment sessions, which means it is also likely to be cost effective and capable of rapid adoption into clinical practice. “

The 5-year trial, funded by the Medical Research Future Fund’s Rare Cancers, Rare Diseases and Unmet Need Grant Opportunity program, will begin this year with planned trial sites in all major states of Australia.

Image credit: ©stock.adobe.com/au/magicmine

]]>
Oregon man diagnosed with ‘terminal’ liver cancer continues to thrive https://rogalevich.org/oregon-man-diagnosed-with-terminal-liver-cancer-continues-to-thrive/ Thu, 24 Feb 2022 18:48:22 +0000 https://rogalevich.org/oregon-man-diagnosed-with-terminal-liver-cancer-continues-to-thrive/ Understanding liver cancer and the importance of second opinions Larry Sullivan was diagnosed with ‘terminal’ liver cancer in 2019. But now, thanks to an individualized treatment approach curated by multiple doctors, he feels better than he has in a long time, with his cancer nearly having faded away. Liver cancer begins in the liver, an […]]]>

Understanding liver cancer and the importance of second opinions

  • Larry Sullivan was diagnosed with ‘terminal’ liver cancer in 2019. But now, thanks to an individualized treatment approach curated by multiple doctors, he feels better than he has in a long time, with his cancer nearly having faded away.
  • Liver cancer begins in the liver, an organ located below the diaphragm and above the stomach. The most common form of the disease is hepatocellular carcinoma, but there are also other types of liver cancers.
  • One of the greatest cancer researchers of our time told SurvivorNet that people should get “multiple” opinions after a cancer diagnosis.

When Larry Sullivan was diagnosed with “terminal” liver cancer in 2019, his mind started racing. But thanks to an individualized treatment approach from multiple doctors, Sullivan’s cancer is almost gone today.

“It’s so amazing and unexpected for me,” he said where he is today. “It’s been a tough trip but I’m doing great.”

With the help of Oregon Cancer Alliance which strives to bring together leading cancer specialists to provide coordinated expert care, Sullivan received a treatment plan organized by several specialists from different clinics. To begin with, Sullivan underwent radioembolization. This procedure involves injecting small beads (called microspheres) with a radioactive isotope (yttrium-90 or Y-90) attached into the hepatic artery that supplies blood to the liver and gallbladder. Then the beads emit small amounts of radiation to the tumor site for several days.

“It allows us to go to where the tumors are and deliver treatment,” says the interventional radiologist, Dr. Donald Garbett, who performed the procedure. “By delivering the treatment directly into the tumour, the rest of the body doesn’t feel it as it would with other treatment procedures. We were able to treat all of Mr. Sullivan’s tumor and it immediately started to shrink.

From there, Sullivan was prescribed a combination of immunotherapy drugs, Yervoy and Opdivo, to treat the cancer that had spread to his lungs and bones. Immunotherapy, in general, has been shown to be extremely effective in treating several cancers, although it does not work for everyone.

Fighting cancer with the body’s own cells: the immunotherapy revolution

After this treatment, doctors could no longer see the cancer in Sullivan’s lungs and bones. In addition to these treatments, Sullivan also underwent spinal surgery and radiation therapy.

Now Sullivan is feeling well and is returning to work as a part-time school psychologist. He also spends time with his family, travels and even restores boats.

“I’m very lucky. I didn’t even imagine six months ago that this would happen. says Sullivan. “It’s been difficult at times, but now I can do things again and have a little joy in my life. am really excited to have more time with my family.

Understanding Liver Cancer

Liver cancer begins in the liver, an organ located below the diaphragm and above the stomach. American Cancer Society estimates that approximately 41,260 new cases (28,600 in men and 12,660 in women) of primary liver cancer and cancer of the intrahepatic bile ducts will be diagnosed in 2022. The most common form of the disease is hepatocellular carcinoma, but there are also other types of liver cancer.

Several risk factors may increase the risk of developing hepatocellular carcinoma (HCC), including but not limited to the following:

  • Gender (hepatocellular carcinoma is much more common in men than in women)
  • Race/ethnicity (In the United States, Asian Americans and Pacific Islanders have the highest rates of liver cancer, followed by Hispanics/Latinos, American Indians/Alaska Natives , African Americans and Whites)
  • Chronic viral hepatitis
  • Cirrhosis (a disease in which liver cells are damaged and replaced by scar tissue)
  • Excessive consumption of alcohol
  • Smoking
  • Obesity
  • Type 2 diabetes

Cancer survivor Joel Naftelberg learned to dance to his problems

Blood tests, ultrasounds, CT scans (x-ray images), MRIs (medical imaging), and angiograms are usually used to confirm a diagnosis of liver cancer. A liver biopsy, where a small piece of tissue is removed and analyzed for cancer cells, may also be performed.

Often a liver transplant is considered the best plan when the patient is eligible. For cases of recurrent liver cancer and cancer that has spread throughout the body, your doctor may consider targeted therapy, immunotherapy, or chemotherapy as the next step.

The importance of getting a second opinion

After you’ve been diagnosed with cancer, it’s important to remember that you can, and should, talk to other cancer specialists about your disease.

“If I had any advice for you following a cancer diagnosis, it would be to first seek several opinions on the best care”, National Cancer Institute Chief of Surgery Steven Rosenberg said SurvivorNet in a previous interview. “Because finding a doctor who is up to date with the latest information is important.”

RELATED: Second (and third) opinions are important when deciding between surgery or radiation therapy

As we highlight in several areas of SurvivorNet, highly respected doctors sometimes disagree about the right treatment, and advances in genetics and immunotherapy create new options. Moreover, in some cases, the specific treatment is not clearly defined. This is one more reason why it is crucial to understand the potential approaches to your disease.

At the National Cancer Institute, there is a patient referral service that “will guide patients to the right group based on their disease state so that they can access these experimental new treatments,” says Rosenberg.

Cancer research legend urges patients to get multiple opinions

Additionally, getting another opinion can also help you avoid doctor bias. For example, some surgeons have radiotherapy centers. “So there may be a conflict of interest if you go to a surgeon who recommends radiation therapy, because that type of facility is partly owned by that type of facility,” Dr. Jim Hudirector of robotic surgery at Weill Cornell Medical Center, tells SurvivorNet.

Other reasons to get a second opinion include:

  • To see a doctor who is more experienced in treating your type of cancer
  • You have a rare type of cancer
  • There are many ways to treat your cancer
  • You feel like your doctor isn’t listening to you or giving you good advice
  • You have trouble understanding your doctor
  • You do not like the treatment recommended by your doctor or are worried about its possible side effects
  • Your insurance company wants you to get another medical opinion
  • Your cancer is not getting better with your current treatment

Be Insistent, Be Your Own Advocate, Says Leading Expert

Ultimately, being proactive about your health could be a matter of life and death. Learn as much as you can from as many experts as you can, so you know you’ve done your best to take control of your health.

Contributor: Marisa Sullivan

Learn more about SurvivorNet’s rigorous medical review process.

]]>
Patients with cirrhosis have a ‘sufficiently high risk’ of liver cancer https://rogalevich.org/patients-with-cirrhosis-have-a-sufficiently-high-risk-of-liver-cancer/ Wed, 23 Feb 2022 15:40:19 +0000 https://rogalevich.org/patients-with-cirrhosis-have-a-sufficiently-high-risk-of-liver-cancer/ February 23, 2022 2 minute read Source/Disclosures Published by: Source: Tapper E. Presentation: HCC Surveillance: Who, How and Expected Benefits. Presented at: GUILD 2022; February 20-23, 2022 (hybrid meeting). Disclosures: Tapper reports research support from Ambys, Gilead, Novo Nordisk and Valeant. ADD A SUBJECT TO EMAIL ALERTS Receive an email […]]]>

February 23, 2022

2 minute read

Source:

Tapper E. Presentation: HCC Surveillance: Who, How and Expected Benefits. Presented at: GUILD 2022; February 20-23, 2022 (hybrid meeting).


Disclosures: Tapper reports research support from Ambys, Gilead, Novo Nordisk and Valeant.


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Screening for hepatocellular carcinoma is essential in high-risk patients, according to a presentation at the GUILD 2022 conference.

“The incidence of liver cancer is multiplied by several, especially in the South and West. … At the same time as the incidence increases, so does the mortality, almost doubling,” Elliot B Type, MARYLAND, associate professor of medicine at the University of Michigan, said. “When you look under the hood to ask who this is happening to, you can see some very important clues to tell us a bit about where this disease is going.”


“Screen for liver cancer every 6 months and pay attention to the dominant risk factors: namely age, biological sex, history of viral hepatitis and family history of liver cancer.  But in a nutshell, we are interested in the history of cirrhosis and viral hepatitis.  Elliot B. Tapper, MD



Modeled projections to 2030 indicate that while the number of liver cancers has increased and will increase in patients aged 65 to 84, younger age groups will see less incidence of HCC over time. In addition, the incidence of HCC is “several times” higher in men than in women.

While the conventional risk factors for liver cancer — stage of fibrosis and active hepatitis C and hepatitis B status — are still prevalent, Tapper noted that cirrhosis and fatty liver disease have become major drivers of disease.

“Screen for liver cancer every 6 months and pay attention to the dominant risk factors: namely age, biological sex, history of viral hepatitis and family history of liver cancer,” said Tapper, advising participants to follow the recent practical advice of the AASLD. “The age thresholds are different depending on epidemiological factors, which are indicators of how long you’ve had hepatitis B. But in a nutshell, we’re looking at history of cirrhosis and viral hepatitis.”

As for screening modalities, ultrasound is quite popular, although the sensitivity (about 50%) and specificity for detecting early liver cancer is lacking. In addition, hindering factors, such as operator dependency, inconvenience, and patient-to-patient variability, decrease the quality of the analysis and limit its performance. Blood biomarker tests continue to be studied for use in screening populations at risk.

“The people who don’t benefit from screening are those who have a low risk of liver cancer: that is, people who don’t have cirrhosis; people who just have non-cirrhotic fatty liver disease,” Tapper concluded. “Although this is not true at this time, it may become clear in the future that several years after being cured of your hepatitis C, you would have a lower risk, but at this time, as long as you have cirrhosis , you will have sufficiently high risk of liver cancer and should therefore be considered for screening.

]]>
Advanced Liver Cancer Market Overview, Epidemiological Segmentation and Market Report 2032 https://rogalevich.org/advanced-liver-cancer-market-overview-epidemiological-segmentation-and-market-report-2032/ Wed, 16 Feb 2022 01:13:59 +0000 https://rogalevich.org/advanced-liver-cancer-market-overview-epidemiological-segmentation-and-market-report-2032/ DelveInsight added a report on “Advanced Liver Cancer Market“. It covers an overview, its causes, signs and symptoms, and therapies. Major players are involved in the development of therapies for advanced liver cancer. The launch of emerging therapies will have a significant impact on the advanced liver cancer market. Overview of Advanced Liver Cancer Advanced […]]]>

DelveInsight added a report on “Advanced Liver Cancer Market“. It covers an overview, its causes, signs and symptoms, and therapies. Major players are involved in the development of therapies for advanced liver cancer. The launch of emerging therapies will have a significant impact on the advanced liver cancer market.

Overview of Advanced Liver Cancer

Advanced liver cancer is stage IV liver cancer in which the cancer has spread to nearby lymph nodes and may have grown into nearby blood vessels or organs. It doesn’t often metastasize, but when it does, it’s more likely to spread to the lungs and bones. It is further categorized into stages IVA and IVB. In stage IVA, the cancer has grown in the blood vessels or organs around the liver and has spread to the lymph nodes but not to other parts of the body. In stage IVB, the cancer has spread to another part of the body, such as the lungs or the bones.

Get sample report @ https://www.delveinsight.com/sample-request/advanced-liver-cancer-market

Some of the major highlights of the Advanced Liver Cancer Market report

  • The proportion of early-stage hepatocellular carcinoma (HCC) is about 65%, while only 5% of patients are present at an advanced stage in Japan.
  • Incidence rates are significantly higher in males than in females in a number of (mainly older) age groups.
  • Liver cancer is the fifth most common cancer in men and the ninth most common cancer in women.
  • Advanced Liver Cancer Societies such as Ono Pharmaceutical Co. Ltd, Benhealth Biopharmaceutical Co., Ltd., Millennium Pharmaceuticals, Can-Fite BioPharma and many others.
  • Advanced Liver Cancer Therapies such as Nivolumab, CIK and CD3-MUC1, MLN0128, CF102 and several others.

Advanced symptoms of liver cancer

  • lose weight without trying
  • Loss of appetite
  • Upper abdominal pain
  • Nausea and vomiting
  • General weakness and fatigue
  • abdominal swelling
  • Yellowing of your skin and the whites of your eyes (jaundice)
  • White and chalky stools

Advanced Liver Cancer Treatment

Treatments such as radiation therapy may also be used to help relieve pain and other symptoms. Ablation therapy and embolization are other available options that help improve symptoms without surgery. Available targeted therapies have a variety of side effects, such as sorafenib (Nexavar), including fatigue, skin rashes, high blood pressure, hand and foot sores, and loss of appetite. There is therefore a need for several new drugs on the market for appropriate treatment of advanced liver cancer.

Get a preview of the report @ https://www.delveinsight.com/sample-request/advanced-liver-cancer-market

Advanced Liver Cancer Market Insights

When liver cancer is at an advanced stage, treatment will not be able to cure it. It aims to control the cancer, relieve the symptoms and give a good quality of life to the patient. Advanced liver cancer is difficult to treat because it has already spread to other organs as well, so most treatments aim to make patients feel better and possibly live longer. Advanced liver cancer spreads to the lymph nodes or other organs, and because it is widespread, it cannot be treated with surgery. The only option left is to take medication.

Advanced Segmentation of Liver Cancer Epidemiology

  • Total number of incidents
  • Age specific incident cases
  • Gender-specific incidents Cases
  • Diagnosed and treatable cases

Advanced evaluation of emerging liver cancer therapies

Key players such as Benhealth Biopharmaceutical (Shenzhen), Bristol-Myers Squibb, Can-Fite BioPharma and many others are developing therapies for the treatment of patients with advanced liver cancer. CIK and CD3-MUC1 (Benhealth Biopharmaceutical), MLN0128 (Millennium Pharmaceuticals), CF102 (Can-Fite BioPharma) along with other compelling treatment options in clinical trials are expected to increase the overall advanced liver cancer market size.

Request sample report @ https://www.delveinsight.com/sample-request/advanced-liver-cancer-market

Contents

1. Key information

2. Executive Summary of Advanced Liver Cancer

3. Competitive Intelligence Analysis for Advanced Liver Cancer

4. Advanced Liver Cancer: Market Snapshot

5. Advanced liver cancer: background and overview of the disease

6. Patient journey

7. Advanced liver cancer epidemiology and patient population

8. Treatment Algorithm, Current Treatment and Medical Practices

9. Unmet needs in advanced liver cancer

10. Key Parameters of Advanced Liver Cancer Treatment

11. Products marketed for advanced liver cancer

12. Advanced emerging therapies for liver cancer

13. Advanced Liver Cancer: Seven Key Market Insights

14. Attribute analysis

15. 7MM: Market Outlook

16. Overview of Access and Reimbursement for Advanced Liver Cancer

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Abilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a business consulting and market research firm, providing expert business solutions for the life sciences verticals and offering premier consulting services in the areas of R&D, strategy formulation, operations , competitive intelligence, competitive landscape design and mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact: Yash Bhardwaj
E-mail: Send an email
Call: 9193216187
Address:304 S. Jones Boulevard #2432
City: Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

]]>
Maranda Curtis partners with the Adrienne Wilson Liver Cancer Association to fight liver cancer https://rogalevich.org/maranda-curtis-partners-with-the-adrienne-wilson-liver-cancer-association-to-fight-liver-cancer/ Tue, 15 Feb 2022 21:45:43 +0000 https://rogalevich.org/maranda-curtis-partners-with-the-adrienne-wilson-liver-cancer-association-to-fight-liver-cancer/ Maranda Curtis, award-winning gospel and worship singer-songwriter, lends her voice to promote liver cancer prevention in the African American community. The acclaimed music artist has teamed up with Blue Faery: The Adrienne Wilson Liver Cancer Association to create a new Public Service Announcement (PSA) campaign and live stream with doctors and experts on Saturday February […]]]>

Maranda Curtis, award-winning gospel and worship singer-songwriter, lends her voice to promote liver cancer prevention in the African American community. The acclaimed music artist has teamed up with Blue Faery: The Adrienne Wilson Liver Cancer Association to create a new Public Service Announcement (PSA) campaign and live stream with doctors and experts on Saturday February 19 at 1:00 p.m. ET in partnership with the National Black Church Initiative (NBCI) for faith communities titled “Love Your Liver”. The campaign and livestream aims to educate about the importance of liver cancer screenings, which can help at-risk populations catch and treat cancer in its early stages.

Within the African-American community, liver cancer is far more deadly than for the American population. In fact, in 2019, chronic liver disease was the eighth leading cause of death for non-Hispanic blacks aged 45 to 64. Often, liver cancer develops due to hepatitis C, which is twice as common in the black community compared to the general population. Hepatitis C is the main risk factor for hepatocellular carcinoma (HCC), the most common type of liver cancer in American adults. However, in recent years researchers have discovered that early interventions can make all the difference in saving lives.

“I’m proud to lend my voice to the ‘Love Your Liver’ campaign to encourage African Americans to stay diligent about liver cancer screening,” said curtis. “I am grateful to Blue Faery: The Adrienne Wilson Liver Cancer Association for the opportunity to promote a cause vital to the well-being of the African-American community.”

Since its launch 20 years ago, Blue Faery’s mission has been to prevent, treat and cure primary liver cancer, in particular HCC, through research, education and advocacy. Andrea Wilson Woods, founder and president of the non-profit organization, created the organization in memory of her sister, Adrienne, who died of stage IV liver cancer at the age of 15. One of the main goals of the organization is to help educate people about the risk factors for liver cancer and to encourage early detection.

“Over the past few years, scientific research has shown the importance of early detection for people suffering from liver disease or cancer. With liver cancer more aggressively targeting the African American community, it is even more critical that this community receive regular screenings,” said Woods. “We are so grateful to Maranda for their partnership on the ‘Love Your Liver’ campaign and are confident that their assistance in this effort will save lives.”

Maranda released her debut single in 2012 and has continued to grow her fanbase over the past decade with her denominational hits. His powerful new album DIE TO LIVE will be released on February 18, 2022.

For more information on the Love Your Liver campaign, visit https://loveyourliver.us . To learn more about the life and music of Maranda Curtis, visit https://www.iammaranda.com/.

The Love Your Liver campaign is supported by Eisai, Exelixis, Merck, AstraZeneca, Bristol Myers Squibband Genentech.

]]>